Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA

Edgepark adding first-of-its kind, fully automated insulin delivery system to diabetes portfolio


Edgepark to distribute Beta Bionics' new FDA-cleared device for those with Type 1 diabetes six years of age and older

TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio. The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses. Designed for anyone six years of age and older living with Type 1 diabetes, it eliminates the traditional manual work previously involved with using an insulin pump.

"It's deeply critical that our customers have access to the latest innovations that remove complexities to care, especially when managing a disease as complicated as Type 1 diabetes," said Anthony Alvarez, senior vice president and general manager, Edgepark. "Edgepark is thrilled to offer the iLet as a first-of-its-kind device that uses automation to make diabetes simpler to navigate."

The iLet automatically delivers basal, correction, and meal doses based on a user's own real-time health data, providing more freedom to the user in their daily life. The system also learns a user's personal trends to adjust insulin, including how many carbs are normally consumed during meals, corrections needed and more.

A more proactive, simple approach to diabetes management

Debra Brown (RDN, LD, CDCES, IFNCP), a clinical diabetes educator for Edgepark, says that removing the need to carb count* or input extensive background data creates a more proactive approach to a patient's diabetes management plan.

"Carb counting alone is very challenging and can be burdensome for patients," said Brown. "The benefits to not having to count carbs and input programmed basal rates, insulin-to-carbohydrate ratios or insulin sensitivity factors can have a significant positive impact to a patient or caregiver."

Introduced initially in 2017, AID systems automatically determine insulin requirements and adjust insulin delivery based on glucose numbers provided by a connected continuous glucose monitor, also known as a CGM. For example, the iLet is compatible with the Dexcom G6 and G7 CGMs, both available through Edgepark.

While AID systems are not totally hands-off, iLet users only have to input their current weight and, at mealtimes, indicate if their meal had a normal amount of carbs for them ? or less or more than usual. As with any insulin delivery system, users must also be able to load the insulin pump with insulin, insert an infusion set and troubleshoot when challenges occur.

"The first few months of using any new device is deeply critical to long-term success and adherence to that therapy," Brown adds. "Edgepark's dedicated diabetes support staff is here for patients and prescribers alike to help as they get used to a new therapy or device."

In addition to ongoing support, Edgepark's simple order process helps patients navigate the complexities of getting prescribed a new diabetic therapy or device. Customers can browse all options available for diabetes management therapies and accompanying supplies on Edgepark.com to determine what best fits their medical and lifestyle needs and understand upfront what their insurance plan will cover prior to ordering.**

"Our patients now have more options for diabetes management that provide greater peace-of-mind and flexibility on a daily basis," Alvarez said. "Edgepark is also here to support our patients at every step of the way by removing some of the complexities of getting medical supplies through insurance. We handle everything from insurance verification and obtaining proper documentation from physicians to shipping so our customers can turn their focus back to their health and wellbeing."

Once an order is placed, Edgepark works directly with the patient's healthcare provider and insurance plan to verify eligibility, then ships product directly to their doorstep. Edgepark works with more than 1,900 health plans nationwide and all orders are eligible for free shipping. Edgepark customers can also enroll in the company's ContinuCare program, which provides text, call or email reminders and an easy reorder process to simplify ongoing at-home maintenance of therapy.

In addition to diabetes supplies, Edgepark also supports patient's supply needs in several other categories, including ostomy, urology, sleep apnea and wound care.

About Edgepark
Edgepark is a leading provider of supplies direct-to-home, committed to caring and providing patients with solutions that make it easy to choose and receive the products needed to live their best life. Learn more at Edgepark.com.

Media Contact: [email protected]

 

SOURCE Edgepark Medical Supplies


These press releases may also interest you

at 07:30
Canopy Growth Corporation ("Canopy Growth" or the "Company") , today announced that on May 2, 2024, it entered into an exchange and subscription agreement (the "Agreement") with a single institutional investor (the "Investor") pursuant to which...

at 07:17
In a heartfelt message in the heart of spring, Kevin Guest, executive chairman at USANA Health Sciences , shares his insights and support for May's Family Wellness Month, an initiative that highlights the importance of family health and unity....

at 07:10
10 Barrel Brewing Co. ("10 Barrel Brewing Co." or "10 Barrel"), a Pacific Northwestern pioneer in craft brewing, a subsidiary of Tilray Brands, Inc. , unveils its latest creation: Pub Cerveza. Building upon the legacy of the ?Cheap Fun.' family,...

at 07:05
Fulgent Genetics, Inc. ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31,...

at 07:05
2seventy bio, Inc. will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available...

at 07:05
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC)...



News published on and distributed by: